StreetInsider.com News Articles

Form EFFECT Nuvectis Pharma, Inc.

Mon, 23 Feb 2026 06:02:00 -0500

si-local-file:///var/storage/secattach/20260223/26038692.html

Form EFFECT Nuvectis Pharma, Inc.

Mon, 23 Feb 2026 06:02:00 -0500

si-local-file:///var/storage/secattach/20260223/26038692.html

Nuvectis Pharma (NVCT) files $150M mixed shelf

Fri, 13 Feb 2026 16:05:02 -0500

Nuvectis Pharma (NASDAQ: NVCT) has filed $150,000,000 mixed shelf of:

Common Stock

Preferred Stock

Warrants

Debt Securities

Units

Nuvectis Pharma (NVCT) files $150M mixed shelf

Fri, 13 Feb 2026 16:05:02 -0500

Nuvectis Pharma (NASDAQ: NVCT) has filed $150,000,000 mixed shelf of:

Common Stock

Preferred Stock

Warrants

Debt Securities

Units

Form S-3 Nuvectis Pharma, Inc.

Fri, 13 Feb 2026 16:01:00 -0500

si-local-file:///var/storage/secattach/20260213/25999728.html

Form S-3 Nuvectis Pharma, Inc.

Fri, 13 Feb 2026 16:01:00 -0500

si-local-file:///var/storage/secattach/20260213/25999728.html

Form 8-K Nuvectis Pharma, Inc. For: Feb 11

Wed, 11 Feb 2026 08:10:00 -0500

si-local-file:///var/storage/secattach/20260211/25979867.html

Form 8-K Nuvectis Pharma, Inc. For: Feb 11

Wed, 11 Feb 2026 08:10:00 -0500

si-local-file:///var/storage/secattach/20260211/25979867.html

Form 10-K Nuvectis Pharma, Inc. For: Dec 31

Wed, 11 Feb 2026 08:03:00 -0500

si-local-file:///var/storage/secattach/20260211/25979818.html

Form 10-K Nuvectis Pharma, Inc. For: Dec 31

Wed, 11 Feb 2026 08:03:00 -0500

si-local-file:///var/storage/secattach/20260211/25979818.html

Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights

Wed, 11 Feb 2026 07:30:00 -0500

FORT LEE, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the year ended December 31, 2025 and provided an update on recent business progress.

Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, “2025 was an eventful year for Nuvectis, with significant progress made in the NXP900 development program, laying the groundwork for multiple potential data readouts in

Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights

Wed, 11 Feb 2026 07:30:00 -0500

Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights

Wed, 11 Feb 2026 07:30:00 -0500

Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights

Wed, 11 Feb 2026 07:30:00 -0500

Form 4 Nuvectis Pharma, Inc. For: Jan 06 Filed by: BENTSUR RON

Fri, 09 Jan 2026 16:32:00 -0500

si-local-file:///var/storage/secattach/20260109/25831644.html

Form 4 Nuvectis Pharma, Inc. For: Jan 06 Filed by: BENTSUR RON

Fri, 09 Jan 2026 16:32:00 -0500

si-local-file:///var/storage/secattach/20260109/25831644.html

Form 4 Nuvectis Pharma, Inc. For: Jan 06 Filed by: Shemesh Shay

Fri, 09 Jan 2026 16:32:00 -0500

si-local-file:///var/storage/secattach/20260109/25831653.html

Form 4 Nuvectis Pharma, Inc. For: Jan 06 Filed by: Shemesh Shay

Fri, 09 Jan 2026 16:32:00 -0500

si-local-file:///var/storage/secattach/20260109/25831653.html

Form 4 Nuvectis Pharma, Inc. For: Jan 06 Filed by: Poradosu Enrique

Fri, 09 Jan 2026 16:31:00 -0500

si-local-file:///var/storage/secattach/20260109/25831635.html

Form 4 Nuvectis Pharma, Inc. For: Jan 06 Filed by: Poradosu Enrique

Fri, 09 Jan 2026 16:31:00 -0500

si-local-file:///var/storage/secattach/20260109/25831635.html

Form 4 Nuvectis Pharma, Inc. For: Jan 06 Filed by: Carson Michael J.

Fri, 09 Jan 2026 16:30:00 -0500

si-local-file:///var/storage/secattach/20260109/25831609.html

Form 4 Nuvectis Pharma, Inc. For: Jan 06 Filed by: Carson Michael J.

Fri, 09 Jan 2026 16:30:00 -0500

si-local-file:///var/storage/secattach/20260109/25831609.html

Nuvectis Pharma starts phase 1b trial of NXP900 with osimertinib

Wed, 17 Dec 2025 07:00:28 -0500

Nuvectis Pharma, Inc. (NASDAQ: NVCT) announced the initiation of a Phase 1b study evaluating NXP900 in combination with osimertinib for patients with epidermal growth factor receptor mutated non-small cell lung cancer.

The study targets patients whose cancers initially responded to osimertinib treatment but subsequently developed resistance. NXP900 is an oral small molecule drug candidate that inhibits SRC and YES1 kinases. Osimertinib, marketed as Tagrisso by AstraZeneca, is a third-generation EGFR inhibitor used in NSCLC treatment.

Eligible patients include those with unresectable, metastatic or locally advanced EGFR mutated NSCLC who previously received and responded to osimertinib as first or second-line therapy. Patients with

Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC

Wed, 17 Dec 2025 07:00:00 -0500

The study is designed to evaluate the safety and clinical activity of NXP900 in combination with osimertinib in patients with epidermal growth factor receptor mutated (EGFR mut+) non-small cell lung cancer (NSCLC) whose cancers initially responded to treatment with osimertinib but subsequently acquired resistance to treatment

Fort Lee, NJ, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the initiation of the Phase 1b study of NXP900

Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC

Wed, 17 Dec 2025 07:00:00 -0500